Clinical Trial Update: A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome [Phase 3]

View source ↗

Summary

EPX-100 (clemizole hydrochloride) is advancing to Phase 3 for Dravet syndrome and is currently recruiting participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome

Drugs mentioned

• EPX-100 (Clemizole hydrochloride)

Snippet

Sponsor: Epygenix | Conditions: Dravet Syndrome | Phase 3 | Status: RECRUITING